ClinicalTrials.gg
Not yet recruitingNCT07302178BM-SF GlycemiaUpdated Dec 24, 2025

Combined Bitter Melon Extract and Snakehead Fish Powder Supplementation for Glycemic Control in Type 2 Diabetes

An interventional study of Snakehead Fish Powder + Bitter Melon Extract and Placebo Capsule in Type 2 Diabetes Mellitus (T2DM) and Hyperglycemia, sponsored by Universitas Muhammadiyah Surakarta. Not yet recruiting. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-24.

Sponsored by Universitas Muhammadiyah Surakarta · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 8 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Study summary

Type 2 diabetes mellitus (T2DM) remains a major global health problem due to its high prevalence, long-term complications, and substantial economic burden. Conventional antidiabetic therapies, including insulin and oral hypoglycemic agents, may cause significant side effects during long-term use and are contraindicated in certain clinical conditions. Therefore, safe and effective herbal-based alternatives are needed.

Previous preclinical and early clinical studies have shown that bitter melon (Momordica charantia L.) and snakehead fish (Channa striata) possess antidiabetic and anti-inflammatory properties, including improvement in glucose regulation, stimulation of insulin secretion, and regeneration of pancreatic cells. However, clinical evidence on their combined use remains limited.

This randomized, double-blind, placebo-controlled clinical trial aims to evaluate the effect of daily supplementation with a combination of bitter melon extract and snakehead fish powder on glycemic status in adults with Type 2 diabetes mellitus. Ninety eligible participants will be randomly assigned to a treatment group receiving 500 mg/day of the herbal combination or a placebo for 4 weeks. Glycemic status will be assessed primarily through glycated albumin (GA) levels.

The findings of this study are expected to provide scientific evidence regarding the safety and efficacy of this herbal combination as a complementary antidiabetic therapy.

Read the detailed description

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by persistent hyperglycemia caused by impaired insulin sensitivity and progressive β-cell dysfunction. Long-standing hyperglycemia contributes to vascular inflammation, oxidative stress, and the formation of advanced glycation end products (AGEs), leading to complications that affect multiple organ systems including the kidneys, eyes, nerves, and cardiovascular system. The prevalence of T2DM continues to rise globally, particularly in low- and middle-income countries, resulting in a significant public health burden. Although conventional antidiabetic medications such as metformin, sulfonylureas, thiazolidinediones, and insulin effectively control blood glucose levels, long-term use may be associated with adverse effects including gastrointestinal disturbances, hypoglycemia, lactic acidosis, lipodystrophy, and contraindications in patients with hepatic or renal impairment. This situation highlights the need for safer, well-tolerated complementary approaches derived from natural products.

Bitter melon (Momordica charantia L.) has been traditionally used as a hypoglycemic agent and has demonstrated antidiabetic properties through multiple mechanisms, including reduction of glucagon secretion, inhibition of intestinal glucose absorption, enhancement of insulin release, and increased peripheral glucose uptake. Meanwhile, snakehead fish (Channa striata) is known to contain high levels of albumin, essential amino acids, and bioactive peptides that support tissue repair, modulate inflammation, and may contribute to improved pancreatic function. Preclinical studies and preliminary clinical observations suggest that these two natural ingredients possess synergistic potential in improving glycemic control, yet their combined effect has not been adequately evaluated in controlled human trials.

This study is designed as a randomized, double-blind, placebo-controlled clinical trial to assess the efficacy of a daily 500-mg supplementation of combined bitter melon extract and snakehead fish powder in improving glycemic status among adults with T2DM. A total of 90 eligible participants aged 20-65 years will be recruited from several community health centers in Surakarta, Indonesia. Participants will be randomized into intervention and placebo groups, while maintaining their standard antidiabetic therapy (metformin monotherapy). The intervention involves consuming one standardized capsule per day for four weeks. Bitter melon extract is prepared through ethanol maceration and evaporation, whereas snakehead fish powder is produced by steaming, drying, pulverizing, and sieving. Standardized nutrient and phytochemical analyses are conducted to ensure batch consistency and quality.

Glycemic control will be assessed primarily through measurements of glycated albumin (GA), which offers greater sensitivity to short-term glycemic fluctuations compared to HbA1c, and is particularly relevant for patients with variable glucose levels. Fasting plasma glucose will also be evaluated as a secondary outcome. Blood samples will be collected at baseline and at the end of week four. Statistical analyses will include paired t-tests for intragroup comparisons and independent t-tests for between-group comparisons, with significance set at p \< 0.05.

This study is expected to generate scientific evidence on the efficacy and safety of the combined bitter melon-snakehead fish supplement as a complementary therapy for T2DM. The findings may contribute to the development of herbal-based antidiabetic products, support future patent applications, and provide a foundation for larger clinical trials aimed at improving accessible and culturally relevant diabetes management strategies.

02

Conditions studied

  • Type 2 Diabetes Mellitus (T2DM)
  • Hyperglycemia

Keywords

  • Bitter melon extract
  • Momordica charantia
  • Channa striata
  • Glycemic status
03

In context

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

This study's planned enrollment of 80 is close to the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Universitas Muhammadiyah Surakarta is the lead sponsor of 11 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with Type 2 Diabetes Mellitus (DMT2).
  • Fasting plasma glucose ≥ 126 mg/dL and ≤ 200 mg/dL or random blood glucose between 200-300 mg/dL.
  • Age 20-65 years
  • Duration of diabetes 0-15 years.
  • Currently using one class of oral antidiabetic medication (biguanide: metformin).
  • Willing to participate and sign written .

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding; or having impaired kidney or liver function (serum creatinine > 1.5 mg/dL; /SGPT > 2× upper limit).
  • Allergy to snakehead fish powder (Channa striata) or bitter melon extract (Momordica charantia).
  • Using antidiabetic medications other than metformin, or unable/unwilling to comply with study procedures.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Combination of Snakehead Fish Powder + Bitter Melon Extract

    Participants in the experimental group will receive a combined herbal supplement containing Channa striata (snakehead fish) powder and Momordica charantia L. (bitter melon) extract. The supplement is provided in capsule form containing 500 mg per day, administered for 4 weeks.

    Dietary Supplement: Snakehead Fish Powder + Bitter Melon Extract

  • Placebo comparator
    Placebo Capsule

    Participants in the control group will receive placebo capsules identical in appearance, administered once daily for 4 weeks, with no active herbal ingredients

    Other: Placebo Capsule

Interventions

  • Dietary supplementSnakehead Fish Powder + Bitter Melon Extract

    Drug page: Bitter melon extractStudies of Bitter melon extractBitter melon extract pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A 500 mg/day capsule containing a combination of: * Channa striata (snakehead fish) powder * Momordica charantia (bitter melon) ethanol extract Administered orally once daily for 4 weeks

  • OtherPlacebo Capsule

    Capsule identical in size, shape, and color to the intervention capsule, without active ingredients. Administered orally once daily for 4 weeks.

06

What researchers measure

Primary outcomes

  1. Change in Fasting Plasma Glucose (FPG) Level

    Fasting plasma glucose level measured at baseline (week 0) and after 4 weeks of supplementation with the combination of Channa striata (snakehead fish powder) and Momordica charantia (bitter melon extract), compared with placebo.

    Time frame: Baseline and Week 4

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared because the study involves a limited sample size and contains sensitive clinical information. Data access is restricted to protect participant confidentiality and is limited to the research team as approved by the institutional ethics committee.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Feb 2026, 1 month later.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 1 month is below that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2025
First posted
Dec 24, 2025
StartEst.
Jan 1, 2026
Primary completionEst.
Feb 28, 2026
CompletionEst.
Jun 1, 2026
Last update
Dec 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07302178
Lead sponsor
Universitas Muhammadiyah Surakarta
Responsible party
Fahrun Nur Rosyid (Head of Quality Assurance Group, Universitas Muhammadiyah Surakarta) — Principal investigator
First posted
Dec 24, 2025
Start date
Jan 1, 2026 (estimated)
Primary completion
Feb 28, 2026 (estimated)
Completion
Jun 1, 2026 (estimated)
Last update
Dec 24, 2025

Study contacts

Fahrun Nur Rosyid, Doctoral degree
Contact
fnr100@ums.ac.id
+62 8123183523
FIK UMS
principal investigator · Universitas Muhammadiyah Surakarta

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bitter melon extract

Start the discussion